Tysabri and Progressive Multifocal Leukoencephalopathy: Understanding the Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Drug Safety to Occupational Exposure Concerns

This domain has historically provided accessible, structured overviews of general health and science information, often drawing from public registries and literature databases to summarize clinical trial data, drug safety profiles, and therapeutic outcomes. This foundation has served to inform a broad audience about medical interventions and their associated risks in a neutral, evidence-oriented manner. Within this context, discussions of drug safety have naturally included adverse event reporting and post-market surveillance data, such as those available through FDA databases. As we pivot from this general health perspective toward a more specialized occupational exposure concern, the focus narrows to the specific risk environment surrounding the administration of biologic therapies. The transition involves moving from population-level safety summaries to the practical implications for healthcare professionals who handle these agents. In particular, the risk of progressive multifocal leukoencephalopathy associated with Tysabri exposure becomes a salient issue not only for patients but also for clinicians and support staff who may encounter the drug in their daily work. This shift reframes the discussion around the conditions under which exposure occurs and the factors that modulate risk in occupational settings, without delving into mechanistic claims.

Tysabri and PML: A Documented Causal Association

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting that the drug increases the risk of PML. The warning states that risk factors for developing PML include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Trial Evidence and Risk Factors

Clinical trial data provide evidence of PML occurrence. In multiple sclerosis trials, two cases of PML were observed among 1,869 patients treated for a median of 120 weeks. These patients had received Tysabri in addition to interferon beta-1a. In Crohn's disease trials, one case occurred after eight doses among 1,043 patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the risk even with relatively short exposure. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can impair immune surveillance against JCV, allowing reactivation of the virus and subsequent development of PML. The presence of anti-JCV antibodies indicates prior exposure to the virus, which is a prerequisite for PML risk. Longer treatment duration and prior immunosuppressant use further compromise immune function, increasing susceptibility.

Clinical Presentation and Monitoring Recommendations

Clinical presentation of PML includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. The FDA advises healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Regarding causation considerations, the established risk factors and documented cases in clinical trials support a causal relationship between Tysabri and PML. The timeline between exposure and harm can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient, indicating that risk increases with longer treatment duration but can also manifest earlier, especially with additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients, the outcome is often severe, with death or permanent disability being common.

Regulatory Warnings and Risk Mitigation

The adequacy of warnings is addressed through the boxed warning and the TOUCH Prescribing Program, which aim to ensure that patients and healthcare providers are informed of the risk and that monitoring protocols are followed. However, the risk remains significant, and patients must be carefully selected based on risk factor assessment. The FDA label emphasizes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease, as this may further increase PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, the evidence clearly establishes that Tysabri increases the risk of PML through its immunosuppressive mechanism, with identifiable risk factors including anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. Clinical trial data confirm PML cases, and the FDA has mandated stringent monitoring and restricted distribution to mitigate this risk. For patients, the timeline from exposure to harm can range from months to years, and the consequences are often devastating.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of PML with Tysabri?

Tysabri use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic brain infection caused by the JC virus. Risk factors include presence of anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. Clinical trials have documented PML cases in both multiple sclerosis and Crohn's disease patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can impair immune surveillance against JC virus, allowing reactivation and development of PML. The mechanism is well-documented in the FDA label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML?

PML presents with progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis involves brain MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. Immediate discontinuation of Tysabri is recommended if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Label

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.